论文部分内容阅读
目的糖尿病肾病(DN)是糖尿病最常见的微血管并发症,是终末期肾病的主要病因,积极控制糖尿病肾病尿微量白蛋白的进一步增加,可延缓糖尿病肾病的进展。本文通过观察我院80例早期糖尿病肾病治疗前后尿微量白蛋白(UAER)、TC、TG、LDL-C来探讨治疗早期糖尿病肾病的方法。方法将80例早期糖尿病肾病(DN)患者随机分成3组,对照组为积极控制血糖、血压;厄贝沙坦组为在此基础上加口服厄贝沙坦150mg.d-1;厄贝沙坦+辛伐他汀组在厄贝沙坦组基础上加辛伐他汀20mg.d-1。结果两治疗组治疗后较对照组尿白蛋白排泄率均明显减少(P<0.05),厄贝沙坦+辛伐他汀组减少程度较厄贝沙坦组更明显(P<0.05);厄贝沙坦+辛伐他汀组治疗后血脂水平明显下降(P<0.05)。结论表明早期DN患者应用辛伐他汀联合厄贝沙坦治疗能有效延缓肾损害进展。
Purpose Diabetic nephropathy (DN), the most common microvascular complication of diabetes mellitus, is the major cause of end-stage renal disease. It can further control the progression of diabetic nephropathy by further controlling the increase of urinary albumin in diabetic nephropathy. In this paper, 80 cases of early diabetic nephropathy in our hospital before and after treatment of urinary albumin (UAER), TC, TG, LDL-C to explore the treatment of early diabetic nephropathy. Methods Eighty patients with early diabetic nephropathy (DN) were randomly divided into three groups, the control group was positive control of blood glucose and blood pressure; irbesartan group was added on the basis of 150mg.d-1 irbesartan; Tan + Simvastatin group plus irbesartan group plus simvastatin 20mg.d-1. Results Compared with the control group, urinary albumin excretion rate was significantly decreased in both treatment groups (P <0.05), and the decrease in irbesartan + simvastatin group was more obvious than that in irbesartan group (P <0.05) After treatment, the level of blood lipids decreased significantly (P <0.05). Conclusions show that the application of simvastatin combined with irbesartan in early DN patients can effectively delay the progression of renal damage.